Image_1_Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen).JPEG

Image_1_Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen).JPEG

<p>Radioligand therapy is a type of internal radiotherapy combining a short-range radioisotope labeled to a carrier with a high affinity for a specific receptor expressed on tumor cells. Targeted alpha therapy (TAT) combines a high-linear energy transfer (LET) emitter (<sup>225</sup&g...

Full description

Saved in:
Bibliographic Details
Main Author: Maria Luisa Belli (7109243) (author)
Other Authors: Anna Sarnelli (2155678) (author), Emilio Mezzenga (2155687) (author), Francesco Cesarini (9603797) (author), Paola Caroli (9603800) (author), Valentina Di Iorio (3706792) (author), Lidia Strigari (51527) (author), Marta Cremonesi (7109249) (author), Antonino Romeo (9603803) (author), Silvia Nicolini (8678646) (author), Federica Matteucci (4353835) (author), Stefano Severi (544174) (author), Giovanni Paganelli (2325853) (author)
Published: 2020
Subjects:
Cancer
Cancer Cell Biology
Cancer Diagnosis
Cancer Genetics
Cancer Therapy (excl. Chemotherapy and Radiation Therapy)
Chemotherapy
Haematological Tumours
Molecular Targets
Radiation Therapy
Solid Tumours
Oncology and Carcinogenesis not elsewhere classified
target alpha therapy (TAT)
prostate-specific membrane antigen (PSMA)
xerostomia
theragnostic
protectors
dosimetry
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items